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(63.7% vs. 57.6%, p = 0.39). The most common type of eco-
nomic claim was that a product was “less expensive/costs less”
(50.6% in the 1990s vs. 32.2% from 2000–2003). CONCLU-
SION: The frequency of economic-content advertising in medical
journals has declined somewhat in recent years, possibly spurred
by Section 114 of FDAMA. Other factors, such as growth in
communication of health economic information through dossier
submissions to formulary committees in response to unsolicited
requests, may have also played a role.
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SECTOR SECURITY PRICES DURING STOCK MARKET
CRASHES
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OBJECTIVES: To examine the impact of stock market crashes
on domestically-listed pharmaceutical company security prices.
METHODS: An event study methodology was employed to
assess the monthly abnormal returns of ﬁrms with historical
standard industrial classiﬁcations of 2834 (pharmaceutical
preparations) during major stock market crashes from 1929 to
2006. Financial returns were modeled via a single index market
model and the Patell standardized residual test was used to assess
statistical signiﬁcance. An estimation period was deﬁned as (−45,
−6) months and various event windows between months (−5, +5)
were tested relative to the event month of the market crash.
Aggregate results were presented as cumulative average abnor-
mal returns (CAAR). RESULTS: Overall, 10 market crashes were
identiﬁed between 1929 and 2006 wherein marketwide value
decreases equaled or exceeded 20%. Within the pharmaceutical
sector during the (−5, +5) event window, 5 crashes were associ-
ated with signiﬁcantly lower returns than the overall market
(1929, 1962, 1970, 1973, 1987) [CAAR = −18.31%, p < 0.05],
4 were associated with statistically similar returns (1937, 1940,
1946, 2000) [CAAR = −6.80%, p = NS], and 1 noted statisti-
cally higher returns (1990) [CAAR = +3.98%, p < 0.05]. CON-
CLUSION: This econometric analysis of the ﬁnancial markets
indicates that the pharmaceutical sector has historically per-
formed equal to or below the overall market in the months sur-
rounding and including stock market crashes. The implications
of this research suggest that security market assets of drug com-
panies do not offer improved performance during these times of
market instability.
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OBJECTIVES: In India, prescriptions are kept by the patient and
not with the pharmacist; and antibiotics may be obtained with
or without a prescription. Therefore, determining antibiotic use
is problematic, since there are no prescription records. The objec-
tive of this study was to develop a surrogate measure for antibi-
otic use in the community in India. METHODS: Surveillance of
antibiotic use was conducted in different residential areas that fall
under 5 municipal wards of New Delhi, India during December
2003–December 2004. Thirty retail pharmacies were enrolled for
the study and consumption of antibiotic use (bulk purchase data)
was collected by recording the quantities of all antibiotics pur-
chased by these pharmacies every month over one year. “Exit
interviews” were conducted with patients leaving the enrolled
pharmacies. 15–25 exit interviews were conducted for each phar-
macy per month over one year. Consumption of antibiotics was
deﬁned as total number of Deﬁned Daily Dose (DDD)/1000 pop-
ulation and DDD/1000 patients. The denominator for bulk data
was population of the ward and for exit interviews, number of
patients who visited the pharmacy. RESULTS: Bulk purchase data
and exit interview data showed a similar pattern of antibiotic use.
Consumption of antibiotics belonging to the ﬂuoroquinilone
group was much higher than others. Penicillins, cephalosporins
and macrolides showed almost equal usage in the community.
Exit interviews revealed that 22% of persons who visited the phar-
macies bought antibiotics. DDD/1000 patients for ﬂuro-
quinolone, penicillins, cephalosporins and macrolides were
34,493, 15,029, 13,270, and 11,800 respectively. Newer drugs
were used more than older drugs. CONCLUSION: Both drug use
methods are good indicators of antibiotic use in the community.
In future, we will use the exit interviews, since this method is less
dependent on commitment of the pharmacists as well as being a
means to collect additional information on patient perceptions
and prescriber behavior.
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OBJECTIVES: Antihypertensive therapy had been well estab-
lished to reduce hypertension-related morbidities and mortali-
ties, but the therapy option was still controversial. The aim of
this study was to determine whether different anti-hypertensive
agents have different risks of developing stroke in patients of
uncomplicated hypertension. METHODS: We conducted a ret-
rospective cohort study using Taiwan’s National Health Insur-
ance Reimbursement Database between January 1997 and
December 2004. A total of 11,017 patients 30 years old or older,
who were diagnosed as essential hypertension and were initiated
with different classes or combinations of antihypertensive drugs,
that are diuretics, beta-blockers, calcium channel blockers
(CCBs), angiotensin-converting-enzyme (ACE) inhibitors or
angiotensin-II receptor blockers (ARBs) and others, were identi-
ﬁed between January 1999 and December 2004. In these patients
we excluded those who had had other related comorbidities (dia-
betes, ischemic heart diseases and other heart diseases, cere-
brovascular diseases, and renal disorders) before initiation of
antihypertensive treatment. Therefore, 4285 newly diagnosed
uncomplicated hypertensive patients who received antihyperten-
sive therapies were remained for our analysis. We used the time-
dependent proportional hazards regression to analyze the
relative risk of developing ﬁrst-ever stroke among these patients.
RESULTS: There were 148 ﬁrst-ever stroke cases identiﬁed out
of these 4285 uncomplicated hypertensive patients. The hazard
ratio was higher for older patients, for male patients and in those
with poor medical compliance. The hazard ratios were 1.68 for
beta-blockers alone, 2.17 for other classes of antihypertensive
drugs and 4.00 (95% CI, 1.63–9.84) for combination of beta-
blockers and diuretics. Other signiﬁcant risk factors were hospi-
talization in prior months and coexistent use of anti-platelet
agents. CONCLUSION: There were higher hazard ratios of
stroke for certain antihypertensive drugs, alone or combined.
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Old age, male gender, poor medical compliance, hospitalization
and coexistent anti-platelet agents were the other signiﬁcant risk
factors of developing stroke in these uncomplicated hypertensive
patients treated with various antihypertensive agents.
PCV2
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OBJECTIVES: To compare efﬁcacy of rosuvastatin (RSV) and
ezetimibe/simvastatin (E/S) to take dyslipidemic patients to their
LDL-C goals according to ATPIII guidelines in the cardiology
clinical practice. Secondary objective was to compare the efﬁcacy
of both treatments to change lipids levels (LDL-C, TC, TG,
HDL-C ApoB/ApoA1 index) from baseline to week 8.
METHODS: Files from dyslipidemic outpatients in the Cardiol-
ogy Unit of a 3rd level hospital in Mexico City were reviewed
between Jan 2004–Dec 2005. Patients treated with either RSV
10 mg/day or E/S 10/20 mg/day and lipid determinations before
(basal) and after 8 weeks of treatment were included. Regression
models were used to adjust outcome measures for age, sex, CHD,
baseline LDL-C, and therapy duration. To assess the primary
objective, patients were classiﬁed as achieving lipid goals or not
according to ATPIII. Statistic analysis was made with a propor-
tion test. For secondary objectives, mean percent lipid change
(MPLC) achieved by each treatment were noted and differences
detected by Student’s t test with a p < 0.05 for signiﬁcance.
RESULTS: Files from 98 (age 63.1 ± 12.4 years) patients treated
with RSV and 89 (age 65.8 ± 12.8 years) treated with E/S were
reviewed. There were no signiﬁcant differences between groups
at baseline. A total of 81.4% and 46.4% RSV patients achieved
the 2001 and 2004 lipid ATPIII goals respectively, versus 58.4%
and 31.5% E/S patients (p < 0.01). The MPLC were: LDL-C:
RSV −46.7 ± 13.6 versus E/S −35 ± 21.3 (p < 0.001); TC: RSV
−33.6 ± 12.7 versus E/S −25.8 ± 16.7 (p < 0.001); HDL-C: RSV
9.9 ± 16.9 versus E/S 4.17 ± 16.5 (p = 0.012) ApoB/ApoA1
index: RSV −21 ± 29 versus E/S −10.7 ± 20 (p = 0.019). There
were no reports of adverse events with any treatment. CON-
CLUSION: More RSV patients achieved their LDL-C goals than
E/S patients. RSV treatment reduced more LDL-C, TC and
apoB/apoA1 index (atherogenic lipid proﬁle) and higher HDL-
C levels than E/S in the usual clinical practice in Mexican
patients.
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OBJECTIVES: We performed a meta-analysis to determine the
overall effectiveness of statins among hypertensive and non-
hypertensive patients. METHODS: We systematically reviewed
Medline publications from 1985 onwards for placebo-controlled
randomized trials that examined the effect of statins on cardiac
morbidity and mortality. Only trials that followed at least 1000
patients for two or more years were included in the meta-analy-
sis. Outcomes of interest included cardiac or cardiovascular
death, major coronary events, or major cardiovascular events.
Pooled estimates of relative risk were calculated separately for
(i) trials that prospectively randomized hypertensive patients to
statin therapy (ASCOT-LLA & ALLHAT-LLT); (ii) trials that
provided post-hoc cardiac event rates for subgroups of hyper-
tensive patients and non-hypertensive patients; (iii) trials that
provided only the baseline percentage of hypertension in the trial
population; and (iv) trials in (ii) and (iii) combined. The moder-
ating effect of the percentage of hypertensive patients at baseline
on the effectiveness of statins was tested using meta-regression.
RESULTS: Besides the ASCOT-LLA and ALLHAT-LLT, 12 trials
enrolling a total of 69,984 patients met the inclusion criteria.
Overall, in these 12 trials, statin therapy reduced cardiac death
by 24% (relative risk [RR]: 0.76; 95% conﬁdence interval [CI]:
0.71–0.82). Pooled relative risk for cardiac morbidity and mor-
tality was similar for trials in groups i, ii, iii, and iv and ranged
from 0.73–0.78. Relative risk estimates for hypertensive patients
(RR: 0.78; 95% CI: 0.72–0.84) and non-hypertensive (RR: 0.76;
95% CI: 0.72–0.80) subgroups were also similar. Consistent
with the subgroup analysis, the meta-regression showed that the
effect of statins on cardiac morbidity and mortality was not mod-
erated by the percentage of hypertensive patients at baseline (Q
estimate = 1.48; P = 0.22). CONCLUSION: Statin therapy effec-
tively reduces CV morbidity and mortality in both hypertensive
and non-hypertensive patients.
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OBJECTIVES: To compare two-year persistence rates associated
with categories of antihypertensive medications among patients
who were newly prescribed antihypertensive medications in a
Medicaid Population. METHODS: The study is composed of all
continuously enrolled Maryland Medicaid patients aged 18 years
or older, with at least one prescription for selected antihyper-
tensive agents between 7/1/02 and 12/31/02, and no such pre-
scriptions in the preceding 6 months. Patients were followed for
two years since their index date. Selected antihypertensive agents
include angiotensin-converting enzyme inhibitors (ACEI),
angiotensin II antagonists (AIIA), beta-blockers (BB), calcium
channel blockers (CCB), diuretics, and ﬁxed-dose combinations.
Medication Possession Ratio (MPR) was assessed at 120, 240,
360, 480, 600 and 720 days after index date. Persistent was
deﬁned as MPR >= 80%. We used logistic regression and gener-
alized estimating equation (GEE) approaches to compare persis-
tent rates for each drug class at 720 days and over two years,
respectively. RESULTS: A total of 2967 patients qualiﬁed for
inclusion in the study. Persistence rates in the whole study sample
at 120, 240, 360, 480, 600 and 720 days were 41.6%, 29.9%,
22.4%, 17.7%, 14.4% and 11.1%, respectively. ACEIs were
associated with signiﬁcantly higher two-year persistence rates
than other classes, followed by CCBs. For the GEE model, over
two years, persistence rates among patients treated with ACEIs
were signiﬁcantly higher than patients treated with diuretics,
BBs, CCBs, and mixed dose combination therapy. ACEIs were
also associated with a slightly higher yet non-signiﬁcant persis-
tence rate than AIIAs. There were no signiﬁcant differences in
persistence rates among other classes. CONCLUSION: In this
Medicaid population, the antihypertensive medication persis-
tence rates among patients who were new users were critically
low. Persistence rates for ACEI are higher than those for CCBs,
BBs, AIIAs, diuretics and ﬁxed dose combinations.
